Michael Klowden - 06 Dec 2024 Form 4 Insider Report for NKGen Biotech, Inc. (NKGN)

Role
Director
Signature
/s/ Paul Y. Song, as Attorney-in-Fact
Issuer symbol
NKGN
Transactions as of
06 Dec 2024
Transactions value $
$0
Form type
4
Filing time
10 Dec 2024, 21:56:22 UTC
Previous filing
14 Feb 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NKGN Stock Option (right to buy) Award $0 +300,000 $0 300,000 06 Dec 2024 Common Stock 300,000 $1.62 Direct F1
transaction NKGN Stock Option (right to buy) Award $0 +500,000 $0 500,000 06 Dec 2024 Common Stock 500,000 $0.438 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On December 6, 2024, the Reporting Person was granted 300,000 options pursuant to the Company's 2023 Equity Incentive Plan, with 40% vesting immediately as of the grant date, and the remaining options vesting in 20 equal installments on the sixth day of each month, beginning January 6, 2025, and ending August 6, 2026, subject to the Reporting Person's continued service with the Issuer on each respective vesting date.
F2 On December 6, 2024, the Reporting Person was granted 500,000 options pursuant to the Company's 2023 Equity Incentive Plan, vesting in 36 equal installments on the sixth of each month, beginning January 6, 2025, and ending December 6, 2027, subject to the Reporting Person's continued service with the Issuer on each respective vesting date